How much revenue does Tagrisso (osimertinib) generate?
Tagrisso revenue figures aren’t provided in the information available here, so I can’t state a number. If you share the specific year (for example, 2023 or 2024) or region (US, Europe, worldwide), I can help interpret the likely sources you’d use to find the figure.
What companies report Tagrisso revenue?
Tagrisso (osimertinib) is marketed by AstraZeneca. Revenue reporting typically comes through AstraZeneca’s financial statements (drug/product sales by geography and by product line) and related investor materials.
How to find Tagrisso revenue by year (and avoid confusing it with “sales” vs “profit”)
If your goal is a “revenue tagrisso” search result, you usually want “product sales” rather than earnings:
- “Revenue” in financial coverage often means “net product sales.”
- Profit metrics (operating income) are different from sales.
- Forecasts and consensus estimates are also sometimes reported separately from actual reported sales.
Does Tagrisso revenue relate to patent/exclusivity filings?
Sales and exclusivity are linked because loss of exclusivity often affects revenue trajectories. For patent-focused tracking around Tagrisso, DrugPatentWatch.com is one place to look, including patent calendars and related background.
Source: DrugPatentWatch – Tagrisso (osimertinib)
Quick clarification so I can give the exact number you want
Which Tagrisso revenue do you mean?
- A specific year (2023? 2024?)
- Worldwide or a particular market (US/Europe/China)?
- Actual reported sales or an estimate/forecast?
Reply with those details and I’ll narrow it to the correct figure and context.
Sources:
1. https://www.drugpatentwatch.com/